STRATEGIES FOR STUDYING BRAIN DISORDERS

Vol.3 Dopamine Disease States

Vol.3 Dopamine Disease States

Editors:Tomás Palomo, Richard Beninger, Trevor Archer

August 1996

Publisher: Editorial CYM, General Oráa, 47, 28006 MADRID

ISBN: 84-921848-0-9

Pages: 668

Vol.3 Estados Patológicos de la Dopamina

Vol.3 Estados Patológicos de la Dopamina

Editores:Tomás Palomo, Richard Beninger, Trevor Archer

Mayo 1997

Editorial: Editorial CYM, General Oráa, 47, 28006 MADRID

ISBN: 84-921848-1-7

Páginas: 666

Congresos

International Meeting on Dopamine Disease States

Mojácar (Almería)

October 18 - 22 1995

The content of this congress, together with other contributions on the topic, are collected in vol. 3 of the series "Strategies for studying brain disorders". (The book is also available in Spanish).

PROGRAMME

  • Tomás Palomo, Spain.
    Opening Remarks.
  • Erik Clavería, Spain.
    Neuroscience research in Spain and in collaboration with other countries.

S1. DOPAMINE-SCHIZOPHRENIA

  • Sven-Ove Ögren, Sweden.
    The pharmacological profiles of new and awaited anti-psychotic agents.
  • William Deakin, UK.
    Preclinical and clinical evidence for the excitatory amino-acids in schizophrenia.
  • Bita Moghaddam, USA.
    Dopamine-glutamate interactions and Cognitive Deficits.
  • Jeffrey M. Goldstein, USA.
    Pre-clinical tests that predict Clozapine-like atypical antipsychotic actions.
  • S2. DOPAMINE-PARKINSON'S DISEASE.
  • Jogren Scheel-Krüger, Denmark.
    Antagonism and reversal of the MPTP biochemical and behavioural effects in rodents and marmosets by NS 2214, a novel dopamine uptake inhibitor.
  • Trevor Archer, Sweden.
    Dopaminergic-glutamatergic balance in the forebrain: functional studies of movement disorders in rats and mice
  • Juan José López-Lozano, Spain.
    Experience with implantation of fetal mesencephalon in Parkinson's Disease: clinical results in 10 grade IV-V patients.
  • Alberto Portera-Sánchez, Spain.
    Epidemiology, etiology and clinical perspectives of parkisonisms.

S3. DOPAMINE-ADDICTION AND NEUROCHEMISTRY

  • Lew Seiden, USA.
    Methamphetamine (MA) engendered neurotoxicity to dopamine (DA) neurons: mechanism of action.
  • Javier Fernández-Ruiz, Spain.
    Dopaminergic neurons as neurochemical substrates of neurobehavioral effects of marihuana: developmental and adult studies.
  • Miguel Casas-Brugé, Spain.
    Relevance of dopamine systems in chemical addictions.
  • Peter Kalivas, USA.
    Preclinical-clinical aspects of drug-and stress-induced psychosis.

S4. DOPAMINE DISORDER INTERACTIVE STUDIES

  • David Jackson, Sweden.
    Clozapine: New biochemical and behavioural studies on its mechanism of action.
  • Jorge Manzanares, Spain.
    Kappa opioid receptor regulation of nigrostriatal, mesolimbic, tuberoinfundibular and periventricular-hypophysial dopaminergic neurons in the male rat.
  • Richard J. Beninger, Canada.
    Dopamine D1-like receptors and molecular mechanisms of incentive learning.
  • Johan Luthman, Sweden.
    Functional and neurochemical responses to interventions in the developing dopamine system.
  • Rik Broekkamp, The Netherlands.
    Role of dopamine-serotonin interrelationships in psychotropic drug effects.

S5. DOPAMINE-GENERAL CONSIDERATIONS

  • Pierre Sokoloff, France.
    Multiple dopamine receptors: their significance for disease states.
  • Bart Ellenbroek, The Netherlands.
    Dopamine and information processing.
  • Klaus Ebmeier, UK.
    Imaging functional change and dopaminergic activity in depression.
  • Ivan Izquierdo, Brasil.
    Synaptic mechanism in hippocampus, amygdala and enthorhinal cortex involved in memory formation, storage and expression.

S6. DOPAMINE DISEASE STATES

  • Nancy Andreasen, USA.
    Neural substrates of frontal lobe function.
  • Robin Murray, UK.
    Dementia praecox or developmental insanity: a new perspective on an old debate.
  • George Koob, USA.
    Dopamine subtype receptor profiles in reward and abuse.
  • Tim Crow, UK.
    The failure of the dopamine hypothesis and its consequences for the future direction of psychosis research.

Fundación Cerebro y Mente
c/ General Oraa, 47 - 1º E 28006 Madrid, España
Telf: +34 91 561 1267 Fax: +34 91 564 1817
http://www.cermente.com

Resolución mínima: 1024 x 768. Navegadores recomendados: Google Chrome / Firefox 3.5+ / Internet Explorer 9.0+ / Opera 9.0+ / Safari 3.0+